Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

27%

3 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(36.4%)

N/A

4(36.4%)

Phase 3

2(18.2%)

Phase 4

1(9.1%)

11Total

Phase 1(4)

N/A(4)

Phase 3(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT06523114Not ApplicableCompleted

Transcatheter Arterial Embolization for Elbow and Foot Plantar Pain

Role: collaborator

NCT06490328Phase 3Recruiting

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Role: lead

NCT04947631Phase 3Completed

Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia

Role: lead

NCT06021444Not ApplicableCompleted

Efficacy and Safety of DKM420 in Patients With Osteoarthritis of Knee

Role: lead

NCT06021418Not ApplicableUnknown

Efficacy and Safety of DKB-119 in Patients in Crow's Feet

Role: lead

NCT05749380Phase 1Completed

Pharmacokinetics and Safety of AmBisome and DKF-5122

Role: lead

NCT05612958Not ApplicableCompleted

Efficacy and Safety of a 'Graft/Prosthesis, Biomaterial (DKM410)' in the Treatment of Both Nasolabial Folds

Role: lead

NCT05188924Phase 4Unknown

Efficacy and Safety of DKF-306 in Patients With Periodontal Diseases

Role: lead

NCT02352311Phase 1Completed

Safety and Pharmacokinetic Characteristics of DKF-313

Role: lead

NCT02695004Phase 1Completed

Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).

Role: lead

NCT01942551Phase 1Completed

Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride

Role: lead

All 11 trials loaded